Pre-treated Anti-PD-1 Refractory Merkel Cell Carcinoma Successfully Treated with the Combination of PD-1/PD-L1 Axis Inhibitors and TVEC: A Report of Two Cases.
暂无分享，去创建一个
[1] G. Matcuk,et al. Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma , 2018, JAAD case reports.
[2] C. Tannenbaum,et al. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series , 2018, Journal of Immunotherapy for Cancer.
[3] Michael E. Lassman,et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.
[4] D. Schadendorf,et al. Immunotherapy in melanoma: Recent advances and future directions. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[5] P. Ascierto,et al. Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma , 2016, Cancer Immunology, Immunotherapy.